Adding cetuximab or bevacizumab to combination chemotherapy improves survival for patients with KRAS wild-type untreated colorectal cancer, with both treatments offering approximately 30-month overall survival. Genetic testing is crucial to determine the benefit of these treatments.
SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateJun 28, 2014
The phase III RECOURSE trial found that TAS-102 improves overall and progression-free survival in patients with metastatic colorectal cancer refractory to standard therapies. The study showed a median overall survival of 7.1 months for TAS-102, compared to 5.3 months for placebo.
SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateJun 28, 2014